Tech Company Financing Transactions
Primo Biotechnology Funding Round
Private investors participated in a $6.8 million Series A funding round for Primo Biotechnology. This venture round was announced on 7/2/2025.
Transaction Overview
Company Name
Announced On
7/2/2025
Transaction Type
Venture Equity
Amount
$6,800,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
No. 167, Dunhua N. Rd., Songshan Dist. 14F
Taipei, Undisclosea
Taiwan
Taipei, Undisclosea
Taiwan
Phone
Website
Email Address
Overview
Primo Biotechnology embodies disruptive innovation that advances clinical procedures for cancer management with molecular image-guided and targeted diagnosis and therapy. We are determined to lead in precision radiopharmaceutical approaches for the diagnosis and treatment of cancer. Based in Taiwan, Primo is on a mission of promoting medical and radiopharma-tech integrated molecular imaging science for the world. We protect your health and happiness with scientific precision.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ya-Yao Huang
Browse more venture capital transactions:
Prev: 7/2/2025: Terra CO2 Technology venture capital transaction
Next: 7/2/2025: NexQloud venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs